Abstract
Several direct, non–vitamin K antagonist, oral anticoagulants (DOACs) are available for stroke prevention in the setting of atrial fibrillation (AF).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
